What is ARA-290 Peptide (Cibinetide)?

ARA-290 Peptide (Cibinetide) is a laboratory research vial available from Royal Peptides. The listing provides its stated format, quantity, specifications and available batch documentation for qualified laboratory research.

What research category does ARA-290 Peptide (Cibinetide) belong to?

ARA-290 Peptide (Cibinetide) is categorized under repair-pathway research. It may be examined in research involving cellular signaling, inflammatory pathways and tissue-repair mechanisms.

What research methods may involve ARA-290 Peptide (Cibinetide)?

Laboratory investigation of ARA-290 Peptide (Cibinetide) may consider cellular-response markers, inflammatory signaling and controlled laboratory models. Appropriate controls, validated procedures and qualified interpretation are essential.

How does ARA-290 Peptide (Cibinetide) compare with related research compounds?

ARA-290 Peptide (Cibinetide) may differ from other compounds studied in repair and recovery research in structure, targets, signaling profile and experimental application. Comparisons should be based on published literature and controlled laboratory design.

Is third-party testing available for ARA-290 Peptide (Cibinetide)?

Available purity, mass, identity, endotoxin or other batch documentation for ARA-290 Peptide (Cibinetide) may be reviewed on its product page or through the Royal Peptides COA library. Testing availability varies by product and batch.

What does the listed strength of ARA-290 Peptide (Cibinetide) represent?

The listed strength identifies the nominal quantity associated with the ARA-290 Peptide (Cibinetide) product format. Refer to available batch documentation for tested mass or identity information when provided.

How should ARA-290 Peptide (Cibinetide) be stored?

Keep ARA-290 Peptide (Cibinetide) sealed, secured and protected from excessive heat, moisture and direct light. Follow the storage information displayed on the product page, packaging and applicable batch documentation.

Is ARA-290 Peptide (Cibinetide) intended for human consumption?

No. ARA-290 Peptide (Cibinetide) is offered strictly for laboratory and research use only. It is not intended for human consumption, medical treatment, diagnosis or veterinary use.

Batch documentation availableReview available analytical information for the selected research material.

Research Use Only Laboratory Research Materials

Royal Peptides products are offered exclusively for laboratory research, analytical, and scientific applications. Not for human or veterinary use.

01Research Product Information

Royal Peptides supplies compounds intended for controlled laboratory research and analytical applications.

For research and analytical use only
Not intended for human consumption or administration
Not intended for veterinary use
Not represented as a drug, medicine, or therapeutic product
Laboratory researchers are responsible for appropriate protocols and controls

Research Only Laboratory Material Analytical Use

02Lyophilized Product Format

Where applicable, Royal Peptides research materials are supplied in lyophilized form.

Lyophilization is a freeze-drying process used to remove moisture from material under controlled conditions.

Material appearance may differ between compounds and production lots
Lyophilized material may appear as a cake, film, or fragmented material
The quantity of visible material may appear small relative to vial size
Visual appearance alone does not establish identity or purity

03Storage & Laboratory Handling

Storage requirements may vary by compound, formulation, and production lot. Refer to the product label and available product-specific documentation.

Protect research materials from excessive heat
Limit unnecessary exposure to direct light and moisture
Keep containers securely closed when stored
Follow product-specific temperature requirements when provided
Use appropriate laboratory contamination-control procedures

04Packaging & Quality Documentation

Packaging components may vary slightly between production lots. This can include vial closures, cap styles, label positioning, and external packaging.

Check the product label and lot identifier before laboratory use
Inspect the vial and closure for visible shipping damage
Packaging design may differ between batches
Lot-specific analytical documentation may be available in our COA library

View COA Library

ROYAL RESEARCH CATALOG

ARA-290 Peptide (Cibinetide)

Research Material Batch Documentation Secure Checkout

Choose an option

10mg Kit (100mg)
30mg Kit (300mg)

Clear selection

BUY MORE • SAVE MORE Volume Pricing

Standard pricing

10+Shop Kits10-vial kits →

PLEASE REVIEW BEFORE ORDERING Important Product Notice

10-VIAL KITS — VIALS ARE NOT INDIVIDUALLY LABELED
10-vial research kits are supplied without individual vial labels. Product and batch identification are provided with the kit packaging.

RECONSTITUTION MATERIALS
For reconstitution-related research, use Royal Peptides® Reconstitution Solution ↗ or a genuine manufacturer-sealed Hospira® / Pfizer® product where applicable.

SUPPORT NOTICE
Support may be limited when unverified third-party materials are used.

01Research focusedLaboratory research materials

02DocumentedAvailable batch information

03TrackedOrder fulfillment updates

Secure payment VISA link $ ₿

RESEARCH NOTICE

For laboratory and research purposes only.Not intended for human consumption, diagnostic use, therapeutic use, or administration to humans or animals.

View Documentation →

EPO-Derived Research Peptide • Research Use Only

ARA-290 Peptide (Cibinetide) — Research Dossier

ARA-290 peptide, also known as cibinetide, is a synthetic peptide derived from a tissue-protective region of erythropoietin (EPO). It has been investigated in preclinical and clinical research involving innate repair receptor signaling, inflammatory pathways, tissue-protective mechanisms, small nerve fibers and neuropathy-related endpoints.

Compound ARA-290

Research Name Cibinetide

Peptide Length 11 Amino Acids

Research Format Lyophilized

What Is ARA-290 Peptide?

ARA-290 (cibinetide) is an 11-amino-acid synthetic peptide developed from the three-dimensional structure of erythropoietin. Research into the compound has focused on separating EPO-associated tissue-protective signaling from the classical erythropoietic activity responsible for stimulating red blood-cell production.

This distinction has made ARA-290 particularly interesting to researchers investigating how EPO-related signaling pathways may participate in cellular stress responses, inflammation, tissue protection and repair-associated biology without reproducing the conventional hematopoietic activity of EPO.

ARA-290 later became widely referenced in scientific literature as cibinetide.

ARA-290 and the Innate Repair Receptor

A central area of ARA-290 research involves a receptor complex frequently referred to as the innate repair receptor (IRR).

The IRR has been described as a heteromeric receptor involving the erythropoietin receptor and the beta common receptor (βcR / CD131). Research has investigated activation of this pathway during tissue stress, injury and inflammatory signaling.

Simplified Research Pathway

ARA-290 → Innate Repair Receptor → Cellular Signaling → Experimental Tissue-Response Pathways

Investigators have used ARA-290 as a research tool for studying signaling associated with cellular survival, inflammatory regulation and tissue-response mechanisms.

Research Context Mechanistic findings from experimental systems do not establish clinical efficacy or an approved therapeutic use for ARA-290.

ARA-290 vs Erythropoietin (EPO)

ARA-290 originated from research examining the biological activities of erythropoietin. EPO is best known for its role in erythropoiesis, but research has also explored signaling associated with tissue stress and cellular protection.

Erythropoietin

Classical EPO Signaling

Full-length erythropoietin is a glycoprotein hormone with a well-characterized role in stimulating red blood-cell production through classical erythropoietin receptor signaling.

ARA-290 / Cibinetide

Tissue-Protective Research

ARA-290 was designed as a small EPO-derived peptide for investigating tissue-protective receptor pathways without the classical erythropoietic activity associated with full-length EPO.

ARA-290 Research Areas

ARA-290 has been investigated across several areas of experimental and translational research. These studies examine biological mechanisms and research endpoints rather than establishing approved medical uses.

Inflammatory Signaling

Research has examined ARA-290 in experimental systems involving inflammatory signaling and innate repair receptor-associated pathways during cellular and tissue stress.

Peripheral Nerve Research

Cibinetide has been investigated in studies involving peripheral nerve biology, small nerve fibers and sensory-function research endpoints.

Tissue-Protection Research

Preclinical investigations have explored ARA-290 in models of tissue stress and injury to better understand EPO-derived tissue-protective signaling mechanisms.

Cellular Repair Signaling

ARA-290 provides researchers with a defined peptide for examining receptor pathways associated with cellular stress responses, survival signaling and repair-associated biology.

Innate Repair Receptor CD131 EPO-Derived Peptide Inflammation Research Peripheral Nerve Research Small Fiber Research Cellular Signaling Tissue Protection

ARA-290 and Small Fiber Neuropathy Research

One of the better-known areas of cibinetide research involves small fiber neuropathy. Clinical research has investigated ARA-290 in populations with disorders associated with small nerve-fiber dysfunction.

Researchers have evaluated endpoints involving small nerve-fiber structure, sensory function and patient-reported outcomes to examine the biological effects associated with innate repair receptor signaling.

These investigations are important scientifically because they extend ARA-290 research beyond isolated cell systems into controlled human research environments while continuing to examine its underlying biological mechanisms.

Important Distinction Research involving neuropathy does not mean ARA-290 is approved to diagnose, prevent or treat neuropathy. Cibinetide remains an investigational research compound.

ARA-290 and Inflammation Research

Another major area of scientific interest involves the relationship between ARA-290 and inflammatory signaling.

Tissue injury and cellular stress can activate complex inflammatory signaling networks. Research into the innate repair receptor has examined whether EPO-derived signaling can influence these responses while simultaneously participating in tissue-protective mechanisms.

ARA-290 therefore provides a useful experimental compound for investigating the intersection between inflammatory biology, cellular stress responses and repair-associated signaling.

ARA-290 Structure and Research Characteristics

ARA-290 is considerably smaller than full-length erythropoietin. Its 11-amino-acid structure was developed to reproduce specific structural characteristics associated with the tissue-protective region of EPO.

The compact structure allows researchers to investigate a defined EPO-derived signaling sequence independently from the much larger parent glycoprotein.

11-Amino-Acid Peptide Compact synthetic peptide derived from EPO-associated structural research.

Non-Erythropoietic Research Developed to investigate tissue-protective pathways separately from classical red blood-cell stimulation.

Receptor-Focused Research Frequently investigated in connection with innate repair receptor signaling.

ARA-290 Peptide Research Specifications

Compound ARA-290

Alternative Name Cibinetide

Classification EPO-Derived Research Peptide

Length 11 Amino Acids

Form Lyophilized Research Material

Research Focus Innate Repair Receptor

Why Is ARA-290 Studied?

ARA-290 occupies an interesting position in peptide research because it was designed around a specific biological question: can tissue-protective EPO signaling be investigated independently of EPO's classical hematopoietic activity?

This has led researchers to examine cibinetide across models involving innate repair receptor activation, inflammatory signaling, peripheral nerve biology, tissue stress and cellular repair mechanisms.

ARA-290 also illustrates how researchers can derive small, functionally focused peptide sequences from substantially larger biological signaling molecules.

ARA-290 Peptide FAQ

What is ARA-290 peptide?

ARA-290 is an 11-amino-acid synthetic peptide derived from structural research involving erythropoietin. It has been investigated primarily for its interaction with tissue-protective and innate repair receptor-associated signaling pathways.

Is ARA-290 the same as cibinetide?

Yes. Cibinetide is the name commonly used in scientific literature for the investigational peptide originally known as ARA-290.

Is ARA-290 the same as erythropoietin?

No. Erythropoietin is a much larger glycoprotein hormone. ARA-290 is a small synthetic peptide derived from structural research into a tissue-protective region associated with EPO.

What is the innate repair receptor?

The innate repair receptor is a receptor complex studied in connection with tissue stress and protective signaling. Research literature commonly describes it as involving the erythropoietin receptor together with the beta common receptor, also known as CD131.

What is ARA-290 researched for?

ARA-290 has been investigated in research involving innate repair receptor signaling, inflammation, tissue-protective mechanisms, peripheral nerve biology, small nerve fibers and cellular stress responses.

Has ARA-290 been studied in humans?

Yes. Cibinetide has been investigated in human clinical research, including studies examining small fiber neuropathy-related endpoints. Clinical investigation does not establish regulatory approval or therapeutic efficacy.

Does ARA-290 stimulate red blood-cell production?

ARA-290 was specifically developed for research into tissue-protective EPO-related signaling without reproducing the classical erythropoietic activity of full-length erythropoietin.

Is ARA-290 approved for human use?

No. ARA-290 / cibinetide is an investigational research compound and is not an approved medication. Royal Peptides supplies this material strictly for laboratory research purposes.

For Research Use Only ARA-290 (cibinetide) is supplied strictly for laboratory, analytical and research purposes. It is not intended for human or veterinary use, consumption, diagnosis, treatment, prevention or mitigation of any disease or medical condition. Information presented on this page describes areas of scientific investigation and does not constitute medical advice or evidence of clinical efficacy.

ARA-290 Peptide (Cibinetide)

ARA-290 Peptide (Cibinetide) — Research Dossier

What Is ARA-290 Peptide?

ARA-290 and the Innate Repair Receptor